Regenxbio (RGNX) Depreciation & Amortization (CF) (2015 - 2025)

Regenxbio's Depreciation & Amortization (CF) history runs 11 years deep, the most recent figure standing at $3.9 million for Q4 2025.

• On a quarterly basis, Depreciation & Amortization (CF) fell 3.47% year-over-year to $3.9 million in Q4 2025; TTM through Dec 2025 was $15.6 million, a 3.61% decrease from a year earlier, with the FY2025 full-year figure at $15.6 million, down 3.61% from the prior year.
• Depreciation & Amortization (CF) was little changed at $3.9 million in Q4 2025 per RGNX's latest filing, from $3.9 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $4.4 million in Q2 2023 and bottomed at $1.9 million in Q1 2021.
• The 5-year median for Depreciation & Amortization (CF) is $3.9 million (2025), against an average of $3.6 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 67.8% in 2023 and fell 9.4% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $2.6 million in 2021, then soared by 58.33% to $4.1 million in 2022, then advanced by 4.58% to $4.3 million in 2023, then decreased by 7.11% to $4.0 million in 2024, then slipped by 3.47% to $3.9 million in 2025.
• Per Business Quant, the three latest RGNX Depreciation & Amortization (CF) figures stand at $3.9 million (Q4 2025), $3.9 million (Q3 2025), and $3.9 million (Q2 2025).